The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 20, 2024
Filed:
Apr. 19, 2019
Institut National DE LA Sante ET DE LA Recherche Medicale (Inserm), Paris, FR;
Universite DE Rennes 1, Rennes, FR;
Centre Hospitalier Universitaire DE Bordeaux, Talence, FR;
Institut Bergonie, Bordeaux, FR;
Centre National DE LA Recherche Scientifique (Cnrs), Paris, FR;
Universite DE Bordeaux, Bordeaux, FR;
Pierre Vacher, Bordeaux, FR;
Patrick Legembre, Rennes, FR;
Mickael Jean, Rennes, FR;
Patrick Blanco, Bordeaux, FR;
Pierre Van De Weghe, Rennes, FR;
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), Paris, FR;
UNIVERSITE DE RENNES 1, Rennes, FR;
CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, Talence, FR;
INSTITUT BERGONIE, Bordeaux, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris, FR;
UNIVERSITE DE BORDEAUX, Bordeaux, FR;
Abstract
The present invention relates the field of reducing CD95-mediated cell motility in a subject, in particular for their use in the reduction of CD-95 mediated cancer cell motility, the reduction of CD95-mediated lymphocyte motility and/or B cell maturation, or the treatment of B-cell tumors, in a subject. The inventors identified a novel family of compounds having the ability to disrupt CD95/PLCγ1 interaction and to neutralize the CD95-mediated calcium signaling pathway and cell migration in human peripheral blood lymphocytes (PBLs) and Th17 cells. Thus, the present invention relates to compounds of formula (A) as defined in the present text, to a pharmaceutical composition comprising said compounds in a pharmaceutically acceptable medium and to the use of these compounds and compositions as medicament, in particular for their use in the reduction or treatment of the above-mentioned pathologies, and in particular in the treatment of cancers and autoimmune inflammatory disease such as systemic lupus erythematosus, inflammatory condition and Th17-mediated disease.